Results 171 to 180 of about 5,590,035 (204)
Some of the next articles are maybe not open access.
Allogeneic Hematopoietic Stem Cell Transplantation
Therapeutic Apheresis and Dialysis, 2003Abstract: More than 30 years have passed since the first clinical application of allogeneic bone marrow transplantation to treat hematological diseases. In recent years, the availability of peripheral blood and cord blood as additional sources of stem cells other than bone marrow has expanded the applicability of hematopoietic stem cell transplantation.
Shunro, Kai, Hiroshi, Hara
openaire +2 more sources
Allogeneic Hematopoietic Cell Transplantation
2021Allogeneic hematopoietic cell transplantation (HCT) has been firmly integrated in the treatment algorithm of acute myeloid leukemia (AML) patients. Optimization of donor choice, supportive care, conditioning regimens, and monitoring of residual disease have led to a constant improvement of outcomes.
openaire +1 more source
Allogeneic hematopoietic cell transplantation for multiple myeloma
Seminars in Hematology, 2001Some patients with multiple myeloma (MM) who have undergone allogeneic hematopoietic stem cell transplants remain free of disease 5 to 13 years later-a major accomplishment for a malignancy that had been resistant to all investigational therapies. Although it will require longer follow-up to determine how many are truly cured, results for patients with
W I, Bensinger, D, Maloney, R, Storb
openaire +2 more sources
Adenovirus infection in allogeneic hematopoietic cell transplantation
Transplant Infectious Disease, 2023AbstractAdenovirus (AdV) infection occurs in 0–20% of patients in the first 3–4 months after allogeneic hematopoietic cell transplantation (HCT), being higher in pediatric than in adult patients. About 50% of AdV infections involve the blood, which in turn, correlates with an increased risk developing AdV diseases, end‐organ damage, and 6‐month overall
openaire +2 more sources
Nonablative allogeneic hematopoietic stem cell transplantation
Current Opinion in Oncology, 2001During the past few years there has been an explosion of knowledge in nonablative allogeneic stem cell transplantation. This approach to transplantation relies more on the creation of "immunologic space" for engraftment rather than the more traditional approach of creating "physical space" by the application of either intensive radiation or chemical ...
R D, Dansey, R D, Baynes
openaire +2 more sources
Allogeneic Hematopoietic Stem Cell Transplantation for Lymphoma
Clinical Lymphoma, 2004For patients with relapsed or refractory Hodgkin's or non-Hodgkin's lymphomas, allogeneic hematopoietic stem cell transplantation (HSCT) is a treatment option when autologous HSCT fails to achieve durable remission or is deemed inappropriate. Allogeneic HSCT can result in long-term survival even in patients with refractory lymphomas.
Robert M, Dean, Michael R, Bishop
openaire +2 more sources
Allogeneic hematopoietic stem cell transplantation for myelofibrosis
Current Opinion in Hematology, 2006This review summarizes the current status and new developments in allogeneic hemopoietic stem cell transplantation strategies for patients with myelofibrosis with myeloid metaplasia, focusing on novel concepts of allogeneic transplantation with reduced-intensity conditioning.No substantial progress has been made in the conventional management of ...
Giovanni, Barosi, Andrea, Bacigalupo
openaire +2 more sources
Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation
Annual Review of Immunology, 2007Allogeneic hematopoietic stem cell transplantation (HSCT) has evolved into an effective adoptive cellular immunotherapy for the treatment of a number of cancers. The immunobiology of allogeneic HSCT is unique in transplantation in that it involves potential immune recognition and attack between both donor and host.
Lisbeth A, Welniak +2 more
openaire +2 more sources
Allogeneic hematopoietic stem cell transplantation in the elderly
Critical Reviews in Oncology/Hematology, 2007The development of reduced intensity or non-myeloablative conditioning (NST) in preparation for allogeneic stem cell transplantation (SCT) revolutionized the field and led to reconsideration of the dogma of upper age limit that was set up by the transplant centers as an eligibility parameter. Analysis of the literature data showed that NST regimens are
Michael Y, Shapira +5 more
openaire +2 more sources
Allogeneic hematopoietic stem cell transplantation for myelofibrosis
Blood, 2003Abstract Fifty-six patients, 10 to 66 years of age, with idiopathic myelofibrosis (IMF) or end-stage polycythemia vera or essential thrombocythemia received allogeneic hematopoietic cell transplants from related (n = 36) or unrelated (n = 20) donors.
H Joachim, Deeg +18 more
openaire +2 more sources